This trial is active, not recruiting.

Conditions blastocyst time, pronuclear appearance, pronuclear fading, embryo compaction, cleavage times
Treatment macs
Sponsor IVI Madrid
Start date February 2016
End date December 2017
Trial size 60 participants
Trial identifier NCT02214537, MADDA12201301


The embryokinetics may be a new prognostic factor for choosing the human embryos with the highest implantation potential. In order to identify the factors that may affect the rate of embryo cleavage, there are many studies about morphokinetics and culture medium, oxygen tension, oocyte quality or type of medication used for ovarian stimulation. However there are no published data with respect to the influence of sperm DNA fragmentation in the embryo kinetic.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose basic science
Patients with MACS Selection

Primary Outcomes

Time of pronuclear appearance in hours.
time frame: The mean time of appearance of pronuclei is 3.3951 hours in our patients. We are going to evaluate pronuclear appearence time in hours in our study groups

Eligibility Criteria

Male or female participants from 36 years up to 38 years old.

Inclusion Criteria: - Patients 36 to 38 years - Fresh sample semen - Minimum 6 oocytes - Semen sample with at least 5 million/ml and at least 30% of progressive motile sperm. Exclusion Criteria: - Patients younger than 36 or older than 38 years old - Frozen semen sample - Less tan 6 oocytes. - Semen samples with less than 5 million / ml or less than 30% of motile sperm.

Additional Information

Official title Embryo Development Measure Depending on the DNA Sperm Fragmentation
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by IVI Madrid.